E4599 — Carboplatin and Paclitaxel With or Without Bevacizumab in Advanced Non-Squamous NSCLC

Phase 3 · 2006 · Non-Small Cell Lung Cancer

Design

Randomized carboplatin plus paclitaxel with or without bevacizumab, then bevacizumab maintenance.

Population

Untreated advanced non-squamous NSCLC without hemoptysis or CNS metastases.

Primary Endpoint

overall survival (OS)

Key Result

OS 12.3 vs 10.3 mo (HR 0.79) — the first regimen to push median survival past one year in advanced NSCLC.

Guideline Impact

Basis for FDA approval of bevacizumab with chemotherapy in non-squamous NSCLC